These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11437395)

  • 1. Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group.
    Ueoka H; Tanimoto M; Kiura K; Tabata M; Takigawa N; Segawa Y; Takata I; Eguchi K; Okimoto N; Harita S; Kamei H; Shibayama T; Watanabe Y; Hiraki S; Harada M
    Br J Cancer; 2001 Jul; 85(1):9-13. PubMed ID: 11437395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
    Ueoka H; Tabata M; Kiura K; Shibayama T; Gemba K; Segawa Y; Chikamori K; Yonei T; Hiraki S; Harada M
    Br J Cancer; 1999 Feb; 79(5-6):984-90. PubMed ID: 10070901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
    Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
    Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer.
    Kim HS; Kim JH; Kim B; Choi HC; Kwon JH; Choi DR
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1591-7. PubMed ID: 23568282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
    DeVore RF; Johnson DH; Crawford J; Garst J; Dimery IW; Eckardt J; Eckhardt SG; Elfring GL; Schaaf LJ; Hanover CK; Miller LL
    J Clin Oncol; 1999 Sep; 17(9):2710-20. PubMed ID: 10561345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: a phase II study.
    Takigawa N; Fujiwara K; Ueoka H; Kiura K; Tabata M; Hiraki A; Shibayama T; Segawa Y; Kamei H; Hiraki S; Tanimoto M; Harada M
    Anticancer Res; 2003; 23(1B):557-60. PubMed ID: 12680145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.
    Masuda N; Fukuoka M; Fujita A; Kurita Y; Tsuchiya S; Nagao K; Negoro S; Nishikawa H; Katakami N; Nakagawa K; Niitani H
    Br J Cancer; 1998 Jul; 78(2):251-6. PubMed ID: 9683302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
    Kiura K; Takigawa N; Segawa Y; Tabata M; Shibayama T; Gemba K; Bessho A; Fujimoto N; Takata I; Hotta K; Fujiwara K; Tokuda Y; Kuyama S; Shinkai T; Ueoka H; Tanimoto M;
    J Thorac Oncol; 2007 Jan; 2(1):44-50. PubMed ID: 17410009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly administration of irinotecan (CPT-11) plus cisplatin for non-small cell lung cancer.
    Hino M; Kobayashi K; Yoshimura A; Takeda Y; Hisakatsu S; Yoneda S; Gemma A; Moriya H; Kudoh S;
    Anticancer Res; 2006; 26(6C):4697-703. PubMed ID: 17214329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
    Hotta K; Ueoka H; Kiura K; Tabata M; Kuyama S; Satoh K; Kozuki T; Hisamoto A; Hosokawa S; Fujiwara K; Tanimoto M
    Lung Cancer; 2004 Jul; 45(1):77-84. PubMed ID: 15196737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study.
    Cardenal F; Domine M; Massutí B; Carrato A; Felip E; Garrido P; Juan O; Artal A; Barneto I; López-Vivanco G; Balcells M; Rosell R
    Lung Cancer; 2003 Feb; 39(2):201-7. PubMed ID: 12581574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
    Frasci G; Comella P; Thomas R; Di Bonito M; Lapenta L; Capasso I; Botti G; Vallone P; De Rosa V; D'Aiuto G; Comella G
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):25-32. PubMed ID: 14513281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
    Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report.
    Pillot GA; Read WL; Hennenfent KL; Marsh S; Gao F; Viswanathan A; Cummings K; McLeod HL; Govindan R
    J Thorac Oncol; 2006 Nov; 1(9):972-8. PubMed ID: 17409981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer.
    Takiguchi Y; Moriya T; Asaka-Amano Y; Kawashima T; Kurosu K; Tada Y; Nagao K; Kuriyama T
    Lung Cancer; 2007 Nov; 58(2):253-9. PubMed ID: 17658654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer.
    Takayama K; Kawasaki M; Ninomiya K; Motohiro A; Fujita M; Watanabe K; Kajiki A; Iwami F; Miyazaki N; Izumi M; Hara N; Nakanishi Y;
    Respirology; 2008 Jan; 13(1):103-7. PubMed ID: 18197918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced nonsmall-cell lung cancer.
    Saito H; Kudoh S; Nakagawa K; Negoro S; Matsui K; Semba H; Takada M
    Am J Clin Oncol; 2006 Oct; 29(5):503-7. PubMed ID: 17023787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.
    Han JY; Lee DH; Lee SY; Park CG; Kim HY; Lee HG; Lee JJ; Kim HT; Lee JS
    Cancer; 2005 Dec; 104(12):2759-65. PubMed ID: 16294344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.